Kalinox (Nitrous Oxide, Oxygen)

Nitrous oxide in Kalinox blocks NMDA receptors, reducing excitatory neurotransmission, and also enhances GABA activity. This dual action produces analgesia, sedation, and a mild anxiolytic effect, while the oxygen component supports normal tissue oxygen levels.

The dose of Kalinox is determined by the prescribing clinician based on the patient’s age, weight, procedure type, and clinical response. Administration is titrated to achieve the desired level of analgesia or sedation.

The safety of Kalinox in pregnancy and lactation has not been fully established. Clinicians should weigh potential benefits against unknown risks and consider alternative analgesic options when treating pregnant or nursing patients.

To order Kalinox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kalinox combines nitrous oxide with oxygen, offering rapid onset of analgesia and sedation with a built‑in safety margin from the oxygen component. Compared with pure nitrous oxide, it reduces the risk of hypoxia, while providing similar efficacy to other inhalational agents such as sevoflurane for short procedures.

Kalinox cylinders should be stored at ambient temperature, kept upright, and protected from heat, direct sunlight and physical impact. Ensure the cylinders are secured to prevent tipping and that the regulator is compatible with medical‑grade gas systems.

Kalinox is delivered via a calibrated inhalation system or mask. The clinician adjusts the flow of the gas mixture to achieve the desired analgesic or sedative effect while continuously monitoring the patient’s respiratory status and oxygen saturation.

Serious risks include hypoxia if oxygen delivery is insufficient, respiratory depression or apnea, loss of consciousness, severe hypotension, cardiac arrhythmias, and rare allergic reactions. Continuous monitoring and appropriate rescue equipment are essential during use.

Kalinox should be avoided in patients with severe COPD, uncontrolled asthma, known hypersensitivity to nitrous oxide or oxygen, those with significant vitamin B12 deficiency, and individuals receiving contraindicated chemotherapy agents unless a specialist determines it is safe.